MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial.

被引：0
|
作者：
Saag, K
Fisher, C
McKay, J
Ehric, E
Zhao, PL
Bolognese, J
Seidenberg, B
Daniels, B
机构：
[1] Univ Iowa, Iowa City, IA 52242 USA
[2] Merck & Co Inc, Rahway, NJ 07065 USA
来源：
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
984
引用
收藏
页码：S196 / S196
页数：1
相关论文
共 6 条
  • [1] MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study.
    Ehrich, E
    Schnitzer, T
    Kivitz, A
    Weaver, A
    Wolfe, F
    Morrison, B
    Zeng, Q
    Bolognese, J
    Seidenberg, B
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 330 - 330
  • [2] MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA) of the knee.
    Gottesdiener, K
    Schnitzer, T
    Fisher, C
    Kafka, S
    Bockow, B
    Dalgin, P
    Markenson, J
    Shahane, A
    Ng, J
    Gertz, B
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S144 - S144
  • [3] Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks.
    Fisher, CA
    Curtis, SP
    Resnick, H
    Ripley, P
    Leung, AT
    Ko, AT
    Bergman, GA
    DeTora, LM
    Gertz, BJ
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S135 - S135
  • [4] Ibuprofen and celecoxib - A comparison of analgesic effects of a non-specific and a specific COX-2 inhibitor: A randomized, placebo-controlled clinical trial.
    Fricke, JA
    Doyle, GA
    Thoden, WR
    Marinucci, LA
    Cooper, SA
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S223 - S223
  • [5] Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, blind, multicentre clinical trial
    Salichs, Marta
    Badiella, Llorenc
    Sarasola, Patxi
    Homedes, Josep
    VETERINARY RECORD, 2022, 191 (06)
  • [6] Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
    Cannon, GW
    Caldwell, JR
    Holt, P
    McLean, B
    Seidenberg, B
    Bolognese, J
    Ehrich, E
    Mukhopadhyay, S
    Daniels, B
    ARTHRITIS AND RHEUMATISM, 2000, 43 (05): : 978 - 987
1